Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Receivables (2016 - 2025)

Protalix BioTherapeutics has reported Receivables over the past 16 years, most recently at $8.8 million for Q4 2025.

  • Quarterly results put Receivables at $8.8 million for Q4 2025, up 203.88% from a year ago — trailing twelve months through Dec 2025 was $8.8 million (up 203.88% YoY), and the annual figure for FY2025 was $8.8 million, up 203.88%.
  • Receivables for Q4 2025 was $8.8 million at Protalix BioTherapeutics, down from $14.4 million in the prior quarter.
  • Over the last five years, Receivables for PLX hit a ceiling of $14.4 million in Q3 2025 and a floor of $1.3 million in Q1 2023.
  • Median Receivables over the past 5 years was $4.6 million (2021), compared with a mean of $5.7 million.
  • Biggest five-year swings in Receivables: crashed 77.93% in 2023 and later skyrocketed 557.18% in 2025.
  • Protalix BioTherapeutics' Receivables stood at $3.4 million in 2021, then skyrocketed by 33.24% to $4.6 million in 2022, then rose by 14.96% to $5.3 million in 2023, then crashed by 44.82% to $2.9 million in 2024, then soared by 203.88% to $8.8 million in 2025.
  • The last three reported values for Receivables were $8.8 million (Q4 2025), $14.4 million (Q3 2025), and $9.4 million (Q2 2025) per Business Quant data.